Skip to main content

Advertisement

SpringerLink
Log in

Batokine in Central Nervous System Diseases

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

Brown adipose tissue (BAT) is a special type of fat tissue in mammals and is also a key endocrine organ in the human body. Batokine, the endocrine effector of BAT, plays a neuroprotective role and improves the prognosis by exerting anti-apoptotic and anti-inflammatory effects, as well as by improving vascular endothelial function and other mechanisms in nerve injury diseases. The present article briefly reviewed several types of batokines related to central nervous system (CNS) diseases. Following this, the potential therapeutic value and future research direction of batokines for CNS diseases were chiefly discussed from the aspects of protective mechanism and signaling pathway.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data Availability

Not applicable.

References

  1. Betz MJ, Enerbäck S (2015) Human brown adipose tissue: what we have learned so far. Diabetes 64:2352–2360. https://doi.org/10.2337/db15-0146

    Article  PubMed  CAS  Google Scholar 

  2. Pinckard KM, Stanford KI (2021) The heartwarming effect of brown adipose Tissue. Mol Pharmacol 102:39–50. https://doi.org/10.1124/molpharm.121.000328

    Article  CAS  Google Scholar 

  3. Cannon B, Nedergaard J (2004) Brown adipose tissue: function and physiological significance. Physiological Reviews 84:277–359. https://doi.org/10.1152/physrev.00015.2003

    Article  PubMed  CAS  Google Scholar 

  4. Nedergaard J, Bengtsson T, Cannon B (2007) Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol-Endocrinol Metab 293:E444–E452. https://doi.org/10.1152/ajpendo.00691.2006

    Article  PubMed  CAS  Google Scholar 

  5. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM et al (2009) Cold-activated brown adipose tissue in healthy men. N Engl J Med 360:1500–1508. https://doi.org/10.1056/nejmoa0808718

    Article  PubMed  Google Scholar 

  6. Cypess AM, Lehman S, Williams G et al (2009) Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360:1509–1517. https://doi.org/10.1056/nejmoa0810780

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Villarroya F, Vidal-Puig A (2013) Beyond the sympathetic tone: the new brown fat activators. Cell Metabolism 17:638–643. https://doi.org/10.1016/j.cmet.2013.02.020

    Article  PubMed  CAS  Google Scholar 

  8. Scheele C, Wolfrum C (2019) Brown adipose crosstalk in tissue plasticity and human metabolism. Endocr Rev 41:53–65. https://doi.org/10.1210/endrev/bnz007

    Article  PubMed Central  Google Scholar 

  9. Townsend KL, Tseng Y-H (2015) Of mice and men: novel insights regarding constitutive and recruitable brown adipocytes. Int J Obes Supp 5:S15–S20. https://doi.org/10.1038/ijosup.2015.5

    Article  CAS  Google Scholar 

  10. Nishio M, Saeki K (2020) The remaining mysteries about brown adipose tissues. Cells 9:2449. https://doi.org/10.3390/cells9112449

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Lehnig AC, Dewal RS, Baer LA, et al (2019) Exercise training induces depot-specific adaptations to white and brown adipose tissue. iScience 11:425–439.https://doi.org/10.1016/j.isci.2018.12.033

  12. Cannon B, Jong JMA, Fischer AW et al (2020) Human brown adipose tissue: classical brown rather than brite/beige? Exp Physiol 105:1191–1200. https://doi.org/10.1113/ep087875

    Article  PubMed  CAS  Google Scholar 

  13. de Jong JMA, Sun W, Pires ND et al (2019) Human brown adipose tissue is phenocopied by classical brown adipose tissue in physiologically humanized mice. Nat Metab 1:830–843. https://doi.org/10.1038/s42255-019-0101-4

    Article  PubMed  Google Scholar 

  14. Villarroya F, Cereijo R, Villarroya J, Giralt M (2016) Brown adipose tissue as a secretory organ. Nat Rev Endocrinol 13:26–35. https://doi.org/10.1038/nrendo.2016.136

    Article  PubMed  CAS  Google Scholar 

  15. Kita S, Maeda N, Shimomura I (2019) Interorgan communication by exosomes, adipose tissue, and adiponectin in metabolic syndrome. J Clin Invest 129:4041–4049. https://doi.org/10.1172/jci129193

    Article  PubMed  PubMed Central  Google Scholar 

  16. Gavaldà-Navarro A, Villarroya J, Cereijo R et al (2021) The endocrine role of brown adipose tissue: an update on actors and actions. Rev Endocr Metab Disord. https://doi.org/10.1007/s11154-021-09640-6

  17. Fon Tacer K, Bookout AL, Ding X et al (2010) Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 24:2050–2064. https://doi.org/10.1210/me.2010-0142

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Rydén M (2009) Fibroblast growth factor 21: an overview from a clinical perspective. Cell Mol Life Sci 66:2067–2073. https://doi.org/10.1007/s00018-009-0003-9

    Article  PubMed  CAS  Google Scholar 

  19. Xie T, Leung PS (2017) Fibroblast growth factor 21: a regulator of metabolic disease and health span. Am J Physiol-Endocrinol Metab 313:E292–E302. https://doi.org/10.1152/ajpendo.00101.2017

    Article  PubMed  PubMed Central  Google Scholar 

  20. Kharitonenkov A (2009) FGFs and metabolism. Curr Opin Pharmacol 9:805–810. https://doi.org/10.1016/j.coph.2009.07.001

    Article  PubMed  CAS  Google Scholar 

  21. Tan BK, Hallschmid M, Adya R et al (2011) Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid. Diabetes 60:2758–2762. https://doi.org/10.2337/db11-0672

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Hsuchou H, Pan W, Kastin AJ (2007) The fasting polypeptide FGF21 can enter brain from blood. Peptides 28:2382–2386. https://doi.org/10.1016/j.peptides.2007.10.007

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Kharitonenkov A, Wroblewski VJ, Koester A et al (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148:774–781. https://doi.org/10.1210/en.2006-1168

    Article  PubMed  CAS  Google Scholar 

  24. Lin Z, Pan X, Wu F et al (2015) Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation 131:1861–1871. https://doi.org/10.1161/circulationaha.115.015308

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Yan X, Chen J, Zhang C et al (2015) FGF 21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation. J Cell Mol Med 19:1557–1568. https://doi.org/10.1111/jcmm.12530

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Yu Y, Bai F, Wang W et al (2015) Fibroblast growth factor 21 protects mouse brain against d-galactose induced aging via suppression of oxidative stress response and advanced glycation end products formation. Pharmacol Biochem Behav 133:122–131. https://doi.org/10.1016/j.pbb.2015.03.020

    Article  PubMed  CAS  Google Scholar 

  27. Huang X, Hu J, Li Y et al (2013) The cell adhesion molecule L1 regulates the expression of FGF21 and enhances neurite outgrowth. Brain Res 1530:13–21. https://doi.org/10.1016/j.brainres.2013.07.043

    Article  PubMed  CAS  Google Scholar 

  28. Sa-nguanmoo P, Chattipakorn N, Chattipakorn SC (2016) Potential roles of fibroblast growth factor 21 in the brain. Metab Brain Dis 31:239–248. https://doi.org/10.1007/s11011-015-9789-3

    Article  PubMed  CAS  Google Scholar 

  29. Sideromenos S, Gundacker A, Nikou M et al (2022) Uncoupling protein-1 modulates anxiety-like behavior in a temperature-dependent manner. J Neurosci 42:7659–7672. https://doi.org/10.1523/jneurosci.2509-21.2022

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Yang X, Hui Q, Yu B et al (2022) Correction to “Design and evaluation of lyophilized fibroblast growth factor 21 and its protection against ischemia cerebral injury.”. Bioconjugate Chem 33:1437–1438. https://doi.org/10.1021/acs.bioconjchem.2c00234

    Article  CAS  Google Scholar 

  31. Kuroda M, Muramatsu R, Maedera N et al (2017) Peripherally derived FGF21 promotes remyelination in the central nervous system. J Clin Invest 127:3496–3509. https://doi.org/10.1172/jci94337

    Article  PubMed  PubMed Central  Google Scholar 

  32. Li S, Yu Y, Li L et al (2015) Treatment of CIA mice with FGF21 down-regulates TH17-IL-17 axis. Inflammation 39:309–319. https://doi.org/10.1007/s10753-015-0251-9

    Article  CAS  Google Scholar 

  33. Hui X, Feng T, Liu Q et al (2016) The FGF21–adiponectin axis in controlling energy and vascular homeostasis. J Mol Cell Biol 8:110–119. https://doi.org/10.1093/jmcb/mjw013

    Article  PubMed  CAS  Google Scholar 

  34. Gómez-Sámano MÁ, Grajales-Gómez M, Zuarth-Vázquez JM et al (2017) Fibroblast growth factor 21 and its novel association with oxidative stress. Redox Biology 11:335–341. https://doi.org/10.1016/j.redox.2016.12.024

    Article  PubMed  CAS  Google Scholar 

  35. Wang N, Li J, Li S et al (2018) Fibroblast growth factor 21 regulates foam cells formation and inflammatory response in Ox-LDL-induced THP-1 macrophages. Biomed Pharmacother 108:1825–1834. https://doi.org/10.1016/j.biopha.2018.09.143

    Article  PubMed  CAS  Google Scholar 

  36. Tanajak P, Chattipakorn SC, Chattipakorn N (2015) Effects of fibroblast growth factor 21 on the heart. J Endocrinol 227:R13–R30. https://doi.org/10.1530/joe-15-0289

    Article  PubMed  CAS  Google Scholar 

  37. Xie Z, Dong X et al (2019) HMGB1-triggered inflammation inhibition of notoginseng leaf triterpenes against cerebral ischemia and reperfusion injury via MAPK and NF-κB signaling pathways. Biomolecules 9:512. https://doi.org/10.3390/biom9100512

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Moskowitz MA, Lo EH, Iadecola C (2010) The science of stroke: mechanisms in search of treatments. Neuron 68:161. https://doi.org/10.1016/j.neuron.2010.08.019

    Article  CAS  Google Scholar 

  39. Wang D, Liu F, Zhu L et al (2020) FGF21 alleviates neuroinflammation following ischemic stroke by modulating the temporal and spatial dynamics of microglia/macrophages. J Neuroinflammation 17(1):257. https://doi.org/10.1186/s12974-020-01921-2

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Tang Y, Le W (2015) Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol 53:1181–1194. https://doi.org/10.1007/s12035-014-9070-5

    Article  PubMed  CAS  Google Scholar 

  41. Ma Y, Wang J, Wang Y, Yang G-Y (2017) The biphasic function of microglia in ischemic stroke. Prog Neurobiol 157:247–272. https://doi.org/10.1016/j.pneurobio.2016.01.005

    Article  PubMed  CAS  Google Scholar 

  42. Bookout AL, de Groot MHM, Owen BM et al (2013) FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med 19:1147–1152. https://doi.org/10.1038/nm.3249

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Kurosu H, Choi M, Ogawa Y et al (2007) Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282:26687–26695. https://doi.org/10.1074/jbc.m704165200

    Article  PubMed  CAS  Google Scholar 

  44. Adams AC, Cheng CC, Coskun T, Kharitonenkov A (2012) FGF21 requires βklotho to act in vivo. PLoS One 7:e49977. https://doi.org/10.1371/journal.pone.0049977

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Itoh N, Ornitz DM (2010) Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 149:121–130. https://doi.org/10.1093/jb/mvq121

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Chen J, Hu J, Liu H et al (2018) FGF21 protects the blood–brain barrier by upregulating PPARγ via FGFR1/β-klotho after traumatic brain injury. J Neurotrauma 35:2091–2103. https://doi.org/10.1089/neu.2017.5271

    Article  PubMed  Google Scholar 

  47. Jiang Y, Liu N, Wang Q et al (2018) Endocrine regulator rFGF21 (recombinant human fibroblast growth factor 21) improves neurological outcomes following focal ischemic stroke of type 2 diabetes mellitus male mice. Stroke 49:3039–3049. https://doi.org/10.1161/strokeaha.118.022119

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Pan J, Jin J, Ge H et al (2015) Malibatol A regulates microglia M1/M2 polarization in experimental stroke in a PPARγ-dependent manner. J Neuroinflammation 14(12):51. https://doi.org/10.1186/s12974-015-0270-3

    Article  CAS  Google Scholar 

  49. Wang H-W, Jiang X, Zhang Y et al (2019) FGF21 protects against hypoxia injury through inducing HSP72 in cerebral microvascular endothelial cells. Front Pharmacol 10. https://doi.org/10.3389/fphar.2019.00101

  50. Xiong T, Tang J, Zhao J et al (2012) Involvement of the Akt/GSK-3β/CRMP-2 pathway in axonal injury after hypoxic–ischemic brain damage in neonatal rat. Neuroscience 216:123–132. https://doi.org/10.1016/j.neuroscience.2012.04.052

    Article  PubMed  CAS  Google Scholar 

  51. Zhang W, Liu J, Hu X et al (2015) n -3 Polyunsaturated fatty acids reduce neonatal hypoxic/ischemic brain injury by promoting phosphatidylserine formation and akt signaling. Stroke 46:2943–2950. https://doi.org/10.1161/strokeaha.115.010815

    Article  PubMed  CAS  Google Scholar 

  52. Pan Y, Wang B, Zheng J et al (2018) Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling-dependent manner. J Cell Mol Med 23:1059–1071. https://doi.org/10.1111/jcmm.14007

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787–795. https://doi.org/10.1038/nature05292

    Article  PubMed  CAS  Google Scholar 

  54. Ballatore C, Lee VM-Y, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 8:663–672. https://doi.org/10.1038/nrn2194

    Article  PubMed  CAS  Google Scholar 

  55. Grundke-Iqbal I, Iqbal K, Tung Y-C et al (1987) Abnormal phosphorylation of the microtubule-associated protein? (tau) in Alzheimer cytoskeletal pathology. Alzheimer Dis Assoc Disord 1:202. https://doi.org/10.1097/00002093-198701030-00020

    Article  Google Scholar 

  56. Long JM, Holtzman DM (2019) Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179:312–339. https://doi.org/10.1016/j.cell.2019.09.001

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Bélanger M, Allaman I, Magistretti PJ (2011) Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 14:724–738. https://doi.org/10.1016/j.cmet.2011.08.016

    Article  PubMed  CAS  Google Scholar 

  58. Garden GA, La Spada AR (2012) Intercellular (mis)communication in neurodegenerative disease. Neuron 73:886–901. https://doi.org/10.1016/j.neuron.2012.02.017

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Escartin C, Valette J, Lebon V, Bonvento G (2006) Neuron?astrocyte interactions in the regulation of brain energy metabolism: a focus on NMR spectroscopy. J Neurochem 99:393–401. https://doi.org/10.1111/j.1471-4159.2006.04083.x

    Article  PubMed  CAS  Google Scholar 

  60. Sun Y, Wang Y, Chen S-T et al (2020) Modulation of the astrocyte-neuron lactate shuttle system contributes to neuroprotective action of fibroblast growth factor 21. Theranostics 10:8430–8445. https://doi.org/10.7150/thno.44370

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Sa-nguanmoo P, Tanajak P, Kerdphoo S et al (2018) FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats. Biomed Pharmacother 97:1663–1672. https://doi.org/10.1016/j.biopha.2017.12.021

    Article  PubMed  CAS  Google Scholar 

  62. Sa-nguanmoo P, Tanajak P, Kerdphoo S et al (2016) FGF21 improves cognition by restored synaptic plasticity, dendritic spine density, brain mitochondrial function and cell apoptosis in obese-insulin resistant male rats. Horm Behav 85:86–95. https://doi.org/10.1016/j.yhbeh.2016.08.006

    Article  PubMed  CAS  Google Scholar 

  63. Mäkelä J, Tselykh TV, Maiorana F et al (2014) Fibroblast growth factor-21 enhances mitochondrial functions and increases the activity of PGC-1α in human dopaminergic neurons via Sirtuin-1. SpringerPlus 3:2. https://doi.org/10.1186/2193-1801-3-2

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Yang C, Wang W, Deng P et al (2021) Fibroblast growth factor 21 modulates microglial polarization that attenuates neurodegeneration in mice and cellular models of Parkinson’s disease. Front Aging Neurosci 13. https://doi.org/10.3389/fnagi.2021.778527

  65. Liddelow SA, Guttenplan KA, Clarke LE et al (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481–487. https://doi.org/10.1038/nature21029

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  66. Qin Y, Qiu J, Wang P et al (2021) Impaired autophagy in microglia aggravates dopaminergic neurodegeneration by regulating NLRP3 inflammasome activation in experimental models of Parkinson’s disease. Brain Behav Immun 91:324–338. https://doi.org/10.1016/j.bbi.2020.10.010

    Article  PubMed  CAS  Google Scholar 

  67. Wang Q, Yuan J, Yu Z et al (2017) FGF21 attenuates high-fat diet-induced cognitive impairment via metabolic regulation and anti-inflammation of obese mice. Mol Neurobiol 55:4702–4717. https://doi.org/10.1007/s12035-017-0663-7

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  68. Campderrós L, Moure R, Cairó M et al (2019) Brown adipocytes secrete GDF15 in response to thermogenic activation. Obesity 27:1606–1616. https://doi.org/10.1002/oby.22584

    Article  PubMed  CAS  Google Scholar 

  69. Strelau J, Sullivan A, Böttner M et al (2000) Growth/differentiation factor-15/macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons in vivo. J Neurosci 20:8597–8603. https://doi.org/10.1523/jneurosci.20-23-08597.2000

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  70. Schober A, Böttner M, Strelau J et al (2001) Expression of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in the perinatal, adult, and injured rat brain. J Comp Neurol 439:32–45. https://doi.org/10.1002/cne.1333

    Article  PubMed  CAS  Google Scholar 

  71. Fuchs T, Trollor JN, Crawford J et al (2013) Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline - the Sydney memory and aging study. Aging Cell 12:882–889. https://doi.org/10.1111/acel.12116

    Article  PubMed  CAS  Google Scholar 

  72. Mu Y, Gage FH (2011) Adult hippocampal neurogenesis and its role in Alzheimer’s disease. Mol Neurodegener 6:85. https://doi.org/10.1186/1750-1326-6-85

    Article  PubMed  PubMed Central  Google Scholar 

  73. Emmerson PJ, Wang F, Du Y et al (2017) The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat Med 23:1215–1219. https://doi.org/10.1038/nm.4393

    Article  PubMed  CAS  Google Scholar 

  74. Yang L, Chang C-C, Sun Z et al (2017) GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat Med 23:1158–1166. https://doi.org/10.1038/nm.4394

    Article  PubMed  CAS  Google Scholar 

  75. Li Z, Wang B, Wu X et al (2005) Identification, expression and functional characterization of the GRAL gene. J Neurochem 95:361–376. https://doi.org/10.1111/j.1471-4159.2005.03372.x

    Article  PubMed  CAS  Google Scholar 

  76. Tan M, Wang Y, Guan K, Sun Y (2000) PTGF-β , a type β transforming growth factor (TGF-β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-β signaling pathway. Proc Natl Acad Sci USA 97:109–114. https://doi.org/10.1073/pnas.97.1.109

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Pagel J-I, Deindl E (2012) Disease progression mediated by Egr-1 associated signaling in response to oxidative stress. IJMS 13:13104–13117. https://doi.org/10.3390/ijms131013104

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  78. Kadowaki M, Yoshioka H, Kamitani H et al (2011) DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines. Int J Cancer 130:267–277. https://doi.org/10.1002/ijc.26082

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Woo SM, Min K, Kim S et al (2014) Silibinin induces apoptosis of HT29 colon carcinoma cells through early growth response-1 (EGR-1)-mediated non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) up-regulation. Chem-Biol Interact 211:36–43. https://doi.org/10.1016/j.cbi.2014.01.004

    Article  PubMed  CAS  Google Scholar 

  80. Yamaguchi H, Nishiyama M, Tokumoto S et al (2021) Elevated cytokine, chemokine, and growth and differentiation factor-15 levels in hemorrhagic shock and encephalopathy syndrome: a retrospective observational study. Cytokine 137:155324. https://doi.org/10.1016/j.cyto.2020.155324

    Article  PubMed  CAS  Google Scholar 

  81. Zhu S, Yang N, Guan Y et al (2021) GDF15 promotes glioma stem cell-like phenotype via regulation of ERK1/2–c-Fos–LIF signaling. Cell Death Discov 7. https://doi.org/10.1038/s41420-020-00395-8

  82. Conte M, Martucci M, Chiariello A et al (2020) Mitochondria, immunosenescence and inflammaging: a role for mitokines? Semin Immunopathol 42:607–617. https://doi.org/10.1007/s00281-020-00813-0

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  83. Rochette L, Zeller M, Cottin Y, Vergely C (2020) Insights into mechanisms of GDF15 and receptor GFRAL: therapeutic targets. Trends Endocrinol Metab 31:939–951. https://doi.org/10.1016/j.tem.2020.10.004

    Article  PubMed  CAS  Google Scholar 

  84. Jin Y-J, Lee J-H, Kim Y-M et al (2012) Macrophage inhibitory cytokine-1 stimulates proliferation of human umbilical vein endothelial cells by up-regulating cyclins D1 and E through the PI3K/Akt-, ERK-, and JNK-dependent AP-1 and E2F activation signaling pathways. Cell Signal 24:1485–1495. https://doi.org/10.1016/j.cellsig.2012.03.014

    Article  PubMed  CAS  Google Scholar 

  85. Schindowski K, von Bohlen und Halbach O, Strelau J et al (2010) Regulation of GDF-15, a distant TGF-β superfamily member, in a mouse model of cerebral ischemia. Cell Tissue Res 343:399–409. https://doi.org/10.1007/s00441-010-1090-5

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  86. Song H, Yin D, Liu Z (2011) GDF-15 promotes angiogenesis through modulating p53/HIF-1α signaling pathway in hypoxic human umbilical vein endothelial cells. Mol Biol Rep 39:4017–4022. https://doi.org/10.1007/s11033-011-1182-7

    Article  PubMed  CAS  Google Scholar 

  87. Park H, Nam K-S, Lee H-J, Kim KS (2022) Ionizing radiation-induced GDF15 promotes angiogenesis in human glioblastoma models by promoting VEGFA expression through p-MAPK1/SP1 signaling. Front Oncol 12. https://doi.org/10.3389/fonc.2022.801230

  88. Li M, Song K, Huang X et al (2018) GDF-15 prevents LPS and D-galactosamine-induced inflammation and acute liver injury in mice. Int J Mol Med. https://doi.org/10.3892/ijmm.2018.3747

  89. Yuan L, Li S, Chen Q et al (2022) EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma. Cell Death Differ 29:1513–1527. https://doi.org/10.1038/s41418-022-00939-8

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  90. Hou K, Shen J, Yan J et al (2021) Loss of TRIM21 alleviates cardiotoxicity by suppressing ferroptosis induced by the chemotherapeutic agent doxorubicin. EBioMedicine 69:103456. https://doi.org/10.1016/j.ebiom.2021.103456

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  91. Xia M, Zhang Q, Zhang Y et al (2022) Growth differentiation factor 15 regulates oxidative stress-dependent ferroptosis post spinal cord injury by stabilizing the p62-Keap1-Nrf2 signaling pathway. Front Aging Neurosci 14. https://doi.org/10.3389/fnagi.2022.905115

  92. Zhang Y, Khan S, Liu Y et al (2022) Modes of brain cell death following intracerebral hemorrhage. Front Cell Neurosci 16. https://doi.org/10.3389/fncel.2022.799753

  93. Chen J, Peng H, Chen C et al (2022) NAG-1/GDF15 inhibits diabetic nephropathy via inhibiting AGE/RAGE-mediated inflammation signaling pathways in C57BL/6 mice and HK-2 cells. Life Sci 311:121142. https://doi.org/10.1016/j.lfs.2022.121142

    Article  PubMed  CAS  Google Scholar 

  94. Brenière C, Méloux A, Pédard M et al (2019) Growth differentiation factor-15 (GDF-15) is associated with mortality in ischemic stroke patients treated with acute revascularization therapy. Front Neurol 10. https://doi.org/10.3389/fneur.2019.00611

  95. Zang Y, Zhu Z, Xie Y et al (2022) Serum growth differentiation factor 15 levels are associated with depression after ischemic stroke. JAHA 11. https://doi.org/10.1161/jaha.121.022607

  96. Worth AA, Shoop R, Tye K et al (2020) The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling. eLife 9. https://doi.org/10.7554/elife.55164

  97. Cimino I, Kim H, Tung YCL et al (2021) Activation of the hypothalamic–pituitary–adrenal axis by exogenous and endogenous GDF15. Proc Natl Acad Sci USA 118. https://doi.org/10.1073/pnas.2106868118

  98. Liu D-D, Lu J-M, Zhao Q-R et al (2016) Growth differentiation factor-15 promotes glutamate release in medial prefrontal cortex of mice through upregulation of T-type calcium channels. Sci Rep 6. https://doi.org/10.1038/srep28653

  99. Wang Y, Zhen C, Wang R, Wang G (2019) Growth-differentiation factor-15 predicts adverse cardiac events in patients with acute coronary syndrome: a meta-analysis. Am J Emerg Med. https://doi.org/10.1016/j.ajem.2019.04.035

  100. Xiong W-P, Yao W-Q, Wang B, Liu K (2021) BMSCs-exosomes containing GDF-15 alleviated SH-SY5Y cell injury model of Alzheimer’s disease via AKT/GSK-3β/β-catenin. Brain Res Bull 177:92–102. https://doi.org/10.1016/j.brainresbull.2021.09.008

    Article  PubMed  CAS  Google Scholar 

  101. Park B-N, Kim J-H, Lim TS et al (2020) Therapeutic effect of mesenchymal stem cells in an animal model of Alzheimer’s disease evaluated by β-amyloid positron emission tomography imaging. Aust N Z J Psychiatry 54:883–891. https://doi.org/10.1177/0004867420917467

    Article  PubMed  Google Scholar 

  102. Maetzler W, Deleersnijder W, Hanssens V et al (2016) GDF15/MIC1 and MMP9 Cerebrospinal fluid levels in Parkinson’s disease and lewy body dementia. PLoS One 11:e0149349. https://doi.org/10.1371/journal.pone.0149349

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Machado V, Haas SJ-P, von Bohlen und Halbach O et al (2016) Growth/differentiation factor-15 deficiency compromises dopaminergic neuron survival and microglial response in the 6-hydroxydopamine mouse model of Parkinson’s disease. Neurobiol Dis 88:1–15. https://doi.org/10.1016/j.nbd.2015.12.016

    Article  PubMed  CAS  Google Scholar 

  104. Machado V, Gilsbach R, Das R et al (2016) Gdf-15 deficiency does not alter vulnerability of nigrostriatal dopaminergic system in MPTP-intoxicated mice. Cell Tissue Res 365:209–223. https://doi.org/10.1007/s00441-016-2406-x

    Article  PubMed  CAS  Google Scholar 

  105. Obeso JA, Rodriguez-Oroz MC, Goetz CG et al (2010) Missing pieces in the Parkinson’s disease puzzle. Nat Med 16:653–661. https://doi.org/10.1038/nm.2165

    Article  PubMed  CAS  Google Scholar 

  106. Ruth M (2012) A PGC1–α–dependent myokine that drives brown–fat–like development of white fat and thermogenesis. Yearbook of Endocrinol 2012:114–116. https://doi.org/10.1016/j.yend.2012.04.012

    Article  Google Scholar 

  107. Yu Q, Kou W, Xu X et al (2019) FNDC5/Irisin inhibits pathological cardiac hypertrophy. Clin Sci 133:611–627. https://doi.org/10.1042/cs20190016

    Article  CAS  Google Scholar 

  108. Tanhaei S, Nikpour P, Ghaedi K et al (2018) RNA/protein discordant expression of Fndc5 in central nervous system is likely to be mediated through microRNAs. DNA Cell Biol 37:373–380. https://doi.org/10.1089/dna.2017.4067

    Article  PubMed  CAS  Google Scholar 

  109. Wrann CD, White JP, Salogiannnis J et al (2013) Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab 18:649–659. https://doi.org/10.1016/j.cmet.2013.09.008

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  110. Torma F, Bori Z, Koltai E et al (2014) Eating habits modulate short term memory and epigenetical regulation of brain derived neurotrophic factor in hippocampus of low- and high running capacity rats. Brain Res Bull 107:54–60. https://doi.org/10.1016/j.brainresbull.2014.07.003

    Article  PubMed  CAS  Google Scholar 

  111. Siteneski A, Olescowicz G, Pazini FL et al (2020) Antidepressant-like and pro-neurogenic effects of physical exercise: the putative role of FNDC5/irisin pathway. J Neural Transm 127:355–370. https://doi.org/10.1007/s00702-020-02143-9

    Article  PubMed  CAS  Google Scholar 

  112. Qin L, Bouchard R, Pugazhenthi S (2016) Regulation of cyclic AMP response element-binding protein during neuroglial interactions. J Neurochem 136:918–930. https://doi.org/10.1111/jnc.13497

    Article  PubMed  CAS  Google Scholar 

  113. Lourenco MV, Ribeiro FC, Sudo FK, et al (2020) Cerebrospinal fluid irisin correlates with amyloid-β, BDNF, and cognition in Alzheimer’s disease. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 12. https://doi.org/10.1002/dad2.12034

  114. Islam MR, Valaris S, Young MF et al (2021) Exercise hormone irisin is a critical regulator of cognitive function. Nat Metab 3:1058–1070. https://doi.org/10.1038/s42255-021-00438-z

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  115. Jodeiri Farshbaf M, Alviña K (2021) Multiple roles in neuroprotection for the exercise derived myokine irisin. Front Aging Neurosci 13. https://doi.org/10.3389/fnagi.2021.649929

  116. Rabiee F, Lachinani L, Ghaedi S et al (2020) New insights into the cellular activities of Fndc5/Irisin and its signaling pathways. Cell Biosci 10. https://doi.org/10.1186/s13578-020-00413-3

  117. Guo P, Liu L, Yang X et al (2022) Irisin improves BBB dysfunction in SAP rats by inhibiting MMP-9 via the ERK/NF-κB signaling pathway. Cell Signal 93:110300. https://doi.org/10.1016/j.cellsig.2022.110300

    Article  PubMed  CAS  Google Scholar 

  118. Zhao R (2022) Irisin at the crossroads of inter-organ communications: challenge and implications. Front Endocrinol 13. https://doi.org/10.3389/fendo.2022.989135

  119. Ahmadi Ghahrizjani F, Ghaedi K, Salamian A et al (2015) Enhanced expression of FNDC5 in human embryonic stem cell-derived neural cells along with relevant embryonic neural tissues. Gene 557:123–129. https://doi.org/10.1016/j.gene.2014.12.010

    Article  CAS  Google Scholar 

  120. Wang Y, Xu E, Musich PR, Lin F (2019) Mitochondrial dysfunction in neurodegenerative diseases and the potential countermeasure. CNS Neurosci Ther 25:816–824. https://doi.org/10.1111/cns.13116

    Article  PubMed  PubMed Central  Google Scholar 

  121. Mani S, Swargiary G, Chadha R (2021) Mitophagy impairment in neurodegenerative diseases: pathogenesis and therapeutic interventions. Mitochondrion 57:270–293. https://doi.org/10.1016/j.mito.2021.01.001

    Article  PubMed  CAS  Google Scholar 

  122. Norris GT, Kipnis J (2018) Immune cells and CNS physiology: microglia and beyond. J Exp Med 216:60–70. https://doi.org/10.1084/jem.20180199

    Article  PubMed  CAS  Google Scholar 

  123. Gelders G, Baekelandt V, Van der Perren A (2018) Linking neuroinflammation and neurodegeneration in Parkinson’s disease. J Immunol Res 2018:1–12. https://doi.org/10.1155/2018/4784268

    Article  CAS  Google Scholar 

  124. Qi J, Yang L, Wang X et al (2022) Irisin: a promising treatment for neurodegenerative diseases. Neuroscience 498:289–299. https://doi.org/10.1016/j.neuroscience.2022.07.018

    Article  PubMed  CAS  Google Scholar 

  125. Lourenco MV, de Freitas GB, Raony Í et al (2022) Irisin stimulates protective signaling pathways in rat hippocampal neurons. Front Cell Neurosci 16. https://doi.org/10.3389/fncel.2022.953991

  126. Lourenco MV, Arancio O, Ferreira ST, De Felice FG (2019) P2-162: Exercise-linked FNDC5/Irisin corrects synaptic plasticity and memory defects in mouse models of Alzheimer’s disease. Alzheimer’s & Dementia 15:P637–P638. https://doi.org/10.1016/j.jalz.2019.06.2569

    Article  Google Scholar 

  127. Noda Y, Kuzuya A, Tanigawa K et al (2018) Fibronectin type III domain-containing protein 5 interacts with APP and decreases amyloid β production in Alzheimer’s disease. Mol Brain 11. https://doi.org/10.1186/s13041-018-0401-8

  128. Tu W-J, Qiu H-C, Cao J-L et al (2018) Decreased concentration of irisin is associated with poor functional outcome in ischemic stroke. Neurotherapeutics 15:1158–1167. https://doi.org/10.1007/s13311-018-0651-2

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  129. Tu T, Peng J, Jiang Y (2020) FNDC5/Irisin: a new protagonist in acute brain injury. Stem Cells Dev 29:533–543. https://doi.org/10.1089/scd.2019.0232

    Article  PubMed  Google Scholar 

  130. Øverberg LT, Lugg EF, Gaarder M et al (2022) Plasma levels of BDNF and EGF are reduced in acute stroke patients. Heliyon 8:e09661. https://doi.org/10.1016/j.heliyon.2022.e09661

    Article  PubMed  PubMed Central  Google Scholar 

  131. Xu X, Zhou R, Ying J et al (2023) Irisin prevents hypoxic-ischemic brain damage in rats by inhibiting oxidative stress and protecting the blood-brain barrier. Peptides 161:170945. https://doi.org/10.1016/j.peptides.2023.170945

    Article  PubMed  CAS  Google Scholar 

  132. Jin Z, Zhang Z, Ke J et al (2021) Exercise-linked irisin prevents mortality and enhances cognition in a mice model of cerebral ischemia by regulating klotho expression. Oxid Med Cell Longevity 2021:1–16. https://doi.org/10.1155/2021/1697070

    Article  CAS  Google Scholar 

  133. Jin Z, Guo P, Li X et al (2019) Neuroprotective effects of irisin against cerebral ischemia/reperfusion injury via Notch signaling pathway. Biomed Pharmacother 120:109452. https://doi.org/10.1016/j.biopha.2019.109452

    Article  PubMed  CAS  Google Scholar 

  134. Zhu D, Wang H, Zhang J et al (2015) Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses. J Mol Cell Cardiol 87:138–147. https://doi.org/10.1016/j.yjmcc.2015.07.015

    Article  PubMed  CAS  Google Scholar 

  135. Lu J, Xiang G, Liu M et al (2015) Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice. Atherosclerosis 243:438–448. https://doi.org/10.1016/j.atherosclerosis.2015.10.020

    Article  PubMed  CAS  Google Scholar 

  136. Wang Y, Tian M, Tan J et al (2022) Irisin ameliorates neuroinflammation and neuronal apoptosis through integrin αVβ5/AMPK signaling pathway after intracerebral hemorrhage in mice. J Neuroinflammation 19. https://doi.org/10.1186/s12974-022-02438-6

  137. Peng J, Deng X, Huang W et al (2017) Irisin protects against neuronal injury induced by oxygen-glucose deprivation in part depends on the inhibition of ROS-NLRP3 inflammatory signaling pathway. Mol Immunol 91:185–194. https://doi.org/10.1016/j.molimm.2017.09.014

    Article  PubMed  CAS  Google Scholar 

  138. Yu Q, Li G, Ding Q et al (2020) Irisin protects brain against ischemia/reperfusion injury through suppressing TLR4/MyD88 pathway. Cerebrovasc Dis 49:346–354. https://doi.org/10.1159/000505961

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Ming Shen and Min Zhang contributed equally to this work and should be considered co-first authors.

Funding

This study was funded by the National Natural Science Foundation of China (82271747).

Author information

Authors and Affiliations

  1. Department of Neonatology, The Second Affiliated Hospital of Wenzhou Medical University and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China

    Ming Shen, Min Zhang, Niping Mao & Zhenlang Lin

  2. Key Laboratory of Perinatal Medicine of Wenzhou, Wenzhou, Zhejiang, China

    Ming Shen, Min Zhang, Niping Mao & Zhenlang Lin

  3. Key Laboratory of Structural Malformations in Children of Zhejiang Province, Wenzhou, Zhejiang, China

    Ming Shen, Min Zhang, Niping Mao & Zhenlang Lin

  4. Zhejiang Provincial Clinical Research Center for Pediatric Disease, Wenzhou, Zhejiang, China

    Ming Shen, Min Zhang, Niping Mao & Zhenlang Lin

Authors
  1. Ming Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Niping Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhenlang Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors Ming Shen, Min Zhang, Niping Mao, and Zhenlang Lin made a significant contribution to the work reported, whether that is in the conception, study design, execution, and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Corresponding author

Correspondence to Zhenlang Lin.

Ethics declarations

Ethics Approval

Not applicable.

Consent to Participate

Not applicable.

Consent for Publication

All the authors read the manuscript carefully and gave their consent for publication.

Competing Interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ming Shen and Min Zhang are co-first authors.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shen, M., Zhang, M., Mao, N. et al. Batokine in Central Nervous System Diseases. Mol Neurobiol 60, 7021–7031 (2023). https://doi.org/10.1007/s12035-023-03490-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-023-03490-w

Keywords

Search

Navigation